The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

Sponsor
Sciberras, Stephen M.D.
Study ID
NCT05035589
Status
Completed

Conditions

  • ARDS
  • COVID-19 Pneumonia

Eligibility Criteria

Sex
ALL
Age
16 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab administered at a dose of 8mg/kg up to a maximum of 800mg

Study Details

This study aims to establish whether tocilizumab has any significant effect on procalcitonin levels on patients diagnosed with COVID-19 pneumonia requiring intensive care admission. The effects on other biochemical and clinical markers are also considered.

Key Dates

Start date
Sep 20, 2021
Status verified
Apr 2023
Primary completion
Oct 20, 2021
Completion
Nov 20, 2021

Study Design

Enrollment
100 participants (actual)

Arms

  • Arm: TCZ
    The first 50 patients admitted to the ITU at Mater Dei Hospital with COVID-19 Pneumonia, to whom tocilizumab was administered
  • Arm: Control
    50 patients admitted to ITU at Mater Dei Hospital with COVID-19 Pneumonia, who did not receive Tocilizumab

Primary Outcome Measure

Procalcitonin [ Time Frame: throughout study completion, daily for maximum of 20 days ]

Related Studies